To overcome the limitations of conventional PDT, we used a similar strategy to develop an Hsp90-targeted PS and demonstrated exquisite tumor selectivity and greater anti-tumor efficacy across molecular and clinical subtypes of BC, including the notoriously aggressive IBC without significant systemic or local toxicity. Here, HSP90AA1 is linked to inflammatory breast carcinoma.